These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 25847818)

  • 21. Rating depression over brief time intervals with the Hamilton Depression Rating Scale: standard vs. abbreviated scales.
    Luckenbaugh DA; Ameli R; Brutsche NE; Zarate CA
    J Psychiatr Res; 2015 Feb; 61():40-5. PubMed ID: 25592045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS; Grant JS; Keltner NL
    Perspect Psychiatr Care; 2013 Jan; 49(1):2-4. PubMed ID: 23293991
    [No Abstract]   [Full Text] [Related]  

  • 23. Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial.
    Phillips JL; Norris S; Talbot J; Birmingham M; Hatchard T; Ortiz A; Owoeye O; Batten LA; Blier P
    Am J Psychiatry; 2019 May; 176(5):401-409. PubMed ID: 30922101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis.
    Lee EE; Della Selva MP; Liu A; Himelhoch S
    Gen Hosp Psychiatry; 2015; 37(2):178-84. PubMed ID: 25698228
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
    Zarate CA; Brutsche NE; Ibrahim L; Franco-Chaves J; Diazgranados N; Cravchik A; Selter J; Marquardt CA; Liberty V; Luckenbaugh DA
    Biol Psychiatry; 2012 Jun; 71(11):939-46. PubMed ID: 22297150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of adipokines in the rapid antidepressant effects of ketamine.
    Machado-Vieira R; Gold PW; Luckenbaugh DA; Ballard ED; Richards EM; Henter ID; De Sousa RT; Niciu MJ; Yuan P; Zarate CA
    Mol Psychiatry; 2017 Jan; 22(1):127-133. PubMed ID: 27046644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Ketamine for treatment of acute depression].
    Hjerrild S; Bjerre J; Pedersen RH; Videbech P
    Ugeskr Laeger; 2013 Sep; 175(37):2090-3. PubMed ID: 24011203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
    Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Systematic Review on the Efficacy of Intravenous Racemic Ketamine for Bipolar Depression.
    Joseph B; Parsaik AK; Ahmed AT; Erwin PJ; Singh B
    J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):71-75. PubMed ID: 33347027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ketamine for the treatment of depression.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2013 Jan; 51(1):11-4. PubMed ID: 23413455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous ketamine for treatment-resistant major depressive disorder.
    Covvey JR; Crawford AN; Lowe DK
    Ann Pharmacother; 2012 Jan; 46(1):117-23. PubMed ID: 22190250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases.
    Paul R; Schaaff N; Padberg F; Möller HJ; Frodl T
    World J Biol Psychiatry; 2009; 10(3):241-4. PubMed ID: 19224412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
    Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A preliminary study of anti-suicidal efficacy of repeated ketamine infusions in depression with suicidal ideation.
    Zhan Y; Zhang B; Zhou Y; Zheng W; Liu W; Wang C; Li H; Chen L; Yu L; Walter M; Li M; Li MD; Ning Y
    J Affect Disord; 2019 May; 251():205-212. PubMed ID: 30927581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
    Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
    J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants.
    Rotroff DM; Corum DG; Motsinger-Reif A; Fiehn O; Bottrel N; Drevets WC; Singh J; Salvadore G; Kaddurah-Daouk R
    Transl Psychiatry; 2016 Sep; 6(9):e894. PubMed ID: 27648916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ketamine augmentation for major depressive disorder and suicidal ideation: Preliminary experience in an inpatient psychiatry setting.
    Sinyor M; Williams M; Belo S; Orser B; Vincent M; Mah L; Zarate C; Castel S; Levitt AJ; Schaffer A
    J Affect Disord; 2018 Dec; 241():103-109. PubMed ID: 30107350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
    Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration.
    Evans JW; Szczepanik J; Brutsché N; Park LT; Nugent AC; Zarate CA
    Biol Psychiatry; 2018 Oct; 84(8):582-590. PubMed ID: 29580569
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.